دورية أكاديمية
P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy
| العنوان: | P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy |
|---|---|
| المؤلفون: | Bertani, L, Tricò, D, Barberio, B, Vernero, M, Bretto, E, Ceccarelli, L, Pardi, V, Calabrese, F, Pasta, A, Bertin, L, Fabiana, Z, Semprucci, G, Bodini, G, Ribaldone, D G, Savarino, E V, Costa, F |
| المصدر: | Journal of Crohn's and Colitis ; volume 18, issue Supplement_1, page i1125-i1125 ; ISSN 1873-9946 1876-4479 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Gastroenterology, General Medicine |
| الوصف: | Background Ustekinumab (UST) is one of the most used biologic drugs for the treatment of Crohn’s Disease (CD) and Ulcerative Colitis (UC). However, not all patients achieve clinical remission and even less mucosal healing. There is currently scarce knowledge about the early markers of therapeutic response in this setting, with particular regard to mucosal healing. The aim of this multicenter study was to evaluate the role of fecal calprotectin (FC) as early predictor of mucosal healing. Methods We enrolled consecutive patients with CD or UC treated with UST for at least 48 weeks at four referral centers in the last 5 years. Therapeutic response was evaluated in terms of clinical remission (defined as a Partial Mayo Score <2 for patients with UC and as Harvey Bradshaw Index <5 for patients with CD, without concomitant corticosteroid therapy) and mucosal healing (defined as a Mayo Endoscopic Score <2 for UC and as the disappearance of ulcers for CD). We collected clinical and demographic data, as well as fecal calprotectin (FC) and C-Reactive Protein (CRP) levels at baseline and at week 24. Results Among 196 patients enrolled (73 [37.2%] women), 167 were affected by CD, whereas 29 by UC. Globally, 128 (65.3%) patients achieved clinical remission and 83 (42.3%) endoscopic remission at 48 weeks of treatment. There were no group differences in age, sex, BMI, baseline clinical and endoscopic indexes, or baseline CRP levels between patients achieving or not either clinical or endoscopic remission. Baseline calprotectin levels were lower in patients who achieved endoscopic remission (median [interquartile range] 391 [103, 1050] versus 825 [317, 1800] µg/mL,p=0.002). At week 24, lower calprotectin levels were observed in both the groups who achieved clinical (160 [50, 426] versus 439 [146, 1000] µg/mL,p<0.0001) and endoscopic remission (114 [43, 265] versus 392 [139, 912] µg/mL,p<0.0001) compared with non-responders. The effects of week-24 calprotectin levels on clinical ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ecco-jcc/jjad212.0706 |
| الإتاحة: | https://doi.org/10.1093/ecco-jcc/jjad212.0706Test https://academic.oup.com/ecco-jcc/article-pdf/18/Supplement_1/i1125/56349610/jjad212.0706.pdfTest |
| حقوق: | https://academic.oup.com/pages/standard-publication-reuse-rightsTest |
| رقم الانضمام: | edsbas.2C1EFF12 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ecco-jcc/jjad212.0706 |
|---|